中国当代儿科杂志2024，Vol.26Issue(1)：19-24,6.DOI:10.7499/j.issn.1008-8830.2308078
关于改善中枢性性早熟患儿身高获益的思考
Considerations on the improvement of height benefit in children with central precocious puberty
梁立阳1
作者信息
- 1. 中山大学孙逸仙纪念医院儿科神经内分泌科,广东广州 510120
- 折叠
摘要
Abstract
With the changes in various factors such as genetics and the environment,the incidence of childhood precocious puberty has been gradually increasing.Improving height is one of the key issues in the clinical management of precocious puberty.Currently,gonadotropin-releasing hormone analogs(GnRHa)remain the preferred treatment for precocious puberty,but their effect on height improvement is influenced by multiple factors,which may result in lower-than-expected height benefits.Combining recombinant human growth hormone(rhGH)therapy with GnRHa treatment is an alternative strategy to enhance the efficacy of GnRHa,but there is still no clear recommendation regarding the timing of their combination.Considering the current status of precocious puberty treatment,it is crucial to reevaluate the effects of GnRHa monotherapy and combination therapy with rhGH on height improvement.This article discusses strategies such as combination therapy indications to guide clinical medication and help children with precocious puberty achieve optimal height benefits.关键词
性早熟/身高获益/促性腺激素释放激素类似物/生长激素/儿童Key words
Precocious puberty/Height benefit/Gonadotropin-releasing hormone analog/Growth hormone/Child引用本文复制引用
梁立阳..关于改善中枢性性早熟患儿身高获益的思考[J].中国当代儿科杂志,2024,26(1):19-24,6.
